Business News
 Business Network
Find good places in Indonesia
The best place for free software on the net
Open source portal software
Direktori website Indonesia paling komplit
Business News / Health
Invida Acquires PT Mugi Laboratories
Thursday, May 20, 2010 09:33:41 Clicks: 3097 Send to a friend Print Version
Singapore, Businesswire -- Invida Group, the leading specialty biopharmaceutical company focused on the commercialization of healthcare products throughout Asia Pacific, today announced that it has completed a joint venture agreement with PT Mugi Laboratories (MUGI), an Indonesian pharmaceutical manufacturer.

The acquisition of MUGI will allow Invida to leverage its full suite of capabilities throughout Indonesia and open up the Indonesian market for Invida’s partners, as well as allowing Invida to offer a range of partnering options unique on this scale in Indonesia.

Local regulations require foreign pharmaceutical entities to operate a local manufacturing facility in order to register their products in the country. With this agreement, Invida will be able to expand its capabilities in Indonesia to include the importation of raw materials and auxiliaries, possession of any and all regulatory licenses for pharmaceutical products, arrangement of toll manufacturing support where needed, in addition to continuing to provide its marketing expertise throughout the archipelago.

John A. Graham, Chief Executive Officer of Invida Group, said, ''Indonesia is a key strategic market and an important growth opportunity for Invida. We continue to work on positioning ourselves as a preferred partner offering full market access, regulatory and commercialization capabilities. Our current sales force in this market has given us a foothold that is unmatched by our international peers, and the ability to offer Invida’s full range of capabilities in Indonesia will be a tremendous benefit to our partners. This will ensure that our partner’s brands can rapidly reach the market and in turn, be accessible to doctors and patients throughout Indonesia. With the acquisition of MUGI, Invida also further cements its role as a single point of entry for those companies looking for a strategic partner to access Asia Pacific markets.''

MUGI’s manufacturing plant currently produces a variety of pharmaceutical products and has offerings in dermatology, consumer health and primary care, which are well aligned with Invida’s strategy and current capabilities. Under the terms of the agreement, Invida has acquired a 70% stake in the company with MUGI’s owners retaining the remaining stake through its investment vehicle. Through Invida’s leadership, the plant will undergo a major upgrade to ensure that it is able to meet all regulatory compliance requirements and the demands of its international partners.

The agreement is mutually beneficial to both parties and enables MUGI to grow its business and leverage Invida’s wide resources and sales force throughout Indonesia. The agreement will allow Invida’s partners to gain fully authorized, unfettered access to the Indonesian pharmaceutical market and to rely on a regional partner who will uphold international standards in manufacturing, licensing, and marketing practices.

Invida Group Pte Ltd --

Invida improves the lives of patients in Asia by commercializing differentiated pharmaceutical products of superior quality - the result of which will allow all our stakeholders to prosper. We do this through our proven brand marketing and sales know-how, strong expertise across a number of key therapeutic categories and deep experience in all critical Asian markets. Comprehensive functional capabilities provide rapid market access delivered by our passionate team of professionals.

With more than 4,000 employees in 13 markets in Asia Pacific, Invida operates across the commercial value chain from regulatory approval and product launch to lifecycle management. We manage a portfolio of proprietary healthcare brands as well as licensed products from small biotech firms and large multinational companies. Partnering is a critical component of Invida’s business model. We collaborate closely with our partners in developing effective strategies and put our extensive experience behind maximizing the potential of the assets entrusted to us.

Invida has corporate headquarters in Science Park Drive, Science Park One, Singapore.

PT Mugi Laboratories

Based in Delta Silicon Industrial Park, Lippo-Cikarang, Bekasi, West Java, Mugi Laboratories manufacturing plant currently produces a variety of pharmaceutical products and has offerings in dermatology, consumer health and primary care.

More Health News
. Shiseido and Sinar Mas Establish PT Shiseido Cosmetics Indonesia
. Asia Pacific In-Vitro Fertilization (IVF) Market 2014-2020
. BPOM Grants IND Approval for SCI to Conduct a Phase II Clinical Trial
. Quintiles and Prodia Partner to Provide Central Lab Testing Solution in Indonesia
. SSI Shredding Systems Helps Convert Industrial Waste to Alternative Fuel
. High-tar Cigarettes Continued to Dominate Indonesian Market
. Indonesia Ranks Among 17 High-Growth Pharmaceutical Markets
. Indonesia Buy First IMDS's Laser Breast Imaging Technology
. Opportunities Assessment for Hepatitis B Therapeutics Market in Indonesia
. Cellegy Grants Distribution Rights for Tostrex to PT Kalbe Farma
Indonesia and Vietnam Pose High Risk for Oil & Gas Companies
Freeport Announces Resumption of Exports from Indonesian Subsidiary
Swift Energy and PT Saka Energi Indonesia to Develop South Texas Gas Field
Technip and Wijaya Karya Secures Onshore Contract for the Matindok Gas Development Project
McDermott Consortium Selected in Gendalo-Gehem Tender Process
Indonesian Automotive Industry, Market Opportunities to 2018
Car Industry Acutely Influenced by Social and Digital Shopping Habits
Indonesia Construction Equipment Market 2014-2018
Indonesia Q1 2012 Car Sales to Remain on a Positive Growth Path
Passenger Vehicles Market in Indonesia Poised to Reach 1 Million in Automotive Sales
 Promo Web
Bengkel Web
Jasa pembuatan website murah dan oke